Revolax Deep — Monophasic HA Filler for Moderate-Deep Wrinkles (1 x 1.1ml)

Revolax Deep is Across Co.’s mid-density variant — 24 mg/mL cross-linked HA + 0.3% lidocaine in a dense monophasic structure. Engineered for mid-to-deep dermal placement targeting moderate-to-deep nasolabial folds, lip augmentation, and cheek volumising. 12-18 months durability per Across clinical data. Bacterially-derived HA (Streptococcus zooepidemicus).

Revolax Deep with Lidocaine is manufactured by Across Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2009. The product is part of the Revolax dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · GMP certified.

Revolax Deep with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Across Co. Ltd.’s Dense Monophasic BDDE Cross-Linking technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Across Co. Ltd.’s clinical data, Revolax Deep with Lidocaine delivers 12-18 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid to deep dermis placement typically delivers the longer end of the duration range.

Revolax Deep with Lidocaine is engineered for mid to deep dermis placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Revolax Deep with Lidocaine regulatory status: KFDA registered · CE marked · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Revolax Deep with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Revolax Deep with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Revolax Deep with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Both share Across Co.’s monophasic HA + 0.3% lidocaine cross-linking platform but differ in HA concentration and intended depth. Revolax Fine (20 mg/mL) is for superficial dermal placement — fine lines, crow’s feet, glabella, neck. Revolax Deep (24 mg/mL) is for mid-to-deep dermal placement — nasolabial folds, lip augmentation, cheek volumising. Deep’s higher HA concentration and cross-linking density support sustained 12-18 month durability versus Fine’s 8-12 months.